Daiichi Sankyo acquired Ranbaxy in an all-cash deal valued at $4.9 billion. Daiichi aimed to expand into generics and emerging markets through the acquisition, while Ranbaxy benefited from access to Daiichi's R&D capabilities and the Japanese market. However, Daiichi failed to adequately address regulatory issues at Ranbaxy facilities that were uncovered after the deal, resulting in billions in write-downs and financial losses for Daiichi.
Case of Daiichi Sankyo takeover of RanbaxyAdityakapoors
This case was prepared with the objective to study merger synergy, valuation and how poor due diligence will have consequences on companies Balance Sheet.
Case of Daiichi Sankyo takeover of RanbaxyAdityakapoors
This case was prepared with the objective to study merger synergy, valuation and how poor due diligence will have consequences on companies Balance Sheet.
Sun Pharma - Ranbaxy Merger PresentationDeepak Shenoy
SunPharma and Ranbaxy merge in 2014 to create India's largest and the world's fifth largest pharma company. The merger, which is all stock, will give Ranbaxy shareholders 0.8 Sun Pharma shares for each share they own.
Sun pharma financial analysis 2008-2017Kushal Shah
This is the financial analysis of sun pharmaceutical india ltd..financial analyis is use for check all the profits and loss during 10 years.pharmaceutical sector affects on a particular pharma company.chages in corporate governance and csr activity can affect more on this analysis.some of the major ratios can affect on shareholders,competitiors.share holders watch it and buy and sell sun pharma companies share.so comment below after watch this ppt.thank you.
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
Sun Pharma - Ranbaxy Merger PresentationDeepak Shenoy
SunPharma and Ranbaxy merge in 2014 to create India's largest and the world's fifth largest pharma company. The merger, which is all stock, will give Ranbaxy shareholders 0.8 Sun Pharma shares for each share they own.
Sun pharma financial analysis 2008-2017Kushal Shah
This is the financial analysis of sun pharmaceutical india ltd..financial analyis is use for check all the profits and loss during 10 years.pharmaceutical sector affects on a particular pharma company.chages in corporate governance and csr activity can affect more on this analysis.some of the major ratios can affect on shareholders,competitiors.share holders watch it and buy and sell sun pharma companies share.so comment below after watch this ppt.thank you.
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
Merger & Acquisition of HDFC Bank with Centurian Bank of PunjabRohan Solanki
The slides show the details of the largest merger in Indian banking sector between HDFC Bank and CBoP.
The benifits and the side effects of the merger are also highlighted in the following presentation
This monthly newsletter provides an overview of the Canadian mutual fund industry vital signs (asset growth, sales and performance, product development highlights for the month and interesting facts about our industry.
This monthly newsletter provides an overview of Canadian mutual fund industry vital signs, product development highlights for the month and interesting facts about our industry.
This monthly newsletter provides an overview of the Canadian mutual fund industry vital signs (asset growth, sales and performance, product development highlights for the month and interesting facts about our industry.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
2. Indian Pharmaceutical Industry-Overview
• India currently represents U.S. $6 billion of the $550 billion global
pharmaceutical industry with its share increasing at 10 % a year.
• Indian sector represents 8% of the global industry total by volume, putting
it in 4th place worldwide, it accounts for 13% by value, and its drug exports
have been growing 30 % annually.
• The “organized” sector of India's pharmaceutical industry consists of 250
to 300 companies, which account for 70 % of products on the market, with
the top 10 firms representing 30 percent.
• India's top 10 pharmaceutical companies were Ranbaxy, Cipla, Dr. Reddy's
Laboratories, Lupin, Nicolas Piramal, Aurobindo Pharma, Cadila
Pharmaceuticals, Sun Pharma, Wockhardt Ltd. and Aventis Pharma.
3. Profile Of Both the Companies
Largest in the India
8th in largest in the global general 2nd largest in Japan
pharmaceuticals 22nd Largest in the world
Serving in over 125 Countries Operations in 50 countries.
Ground operations in 49 countries Producer of high quality
& Manufacturing in 11 countries. drugs
Strong R&D Base.
15th Largest drug maker in the world
Market Capitalization – 30 Billion
Low cost production
4. Last 5 years - Annual results in brief (Figs in Crores)
Dec ' 09 Dec ' 08 Dec ' 07 Dec ' 06 Dec ' 05
4,784.76 4,494.52 4,071.29 3,973.56 3,490.13
Sales
822.89 239.75 546.87 559.45 65.76
Operating profit
(109.85) 893.40 93.43 58.10 26.41
Interest
1,210.12 (562.40) 893.14 580.92 249.01
Gross profit
13.61 (24.56) 16.56 10.37 6.01
EPS (Rs)
5. Strategic Objectives Behind The Deal
Presence in emerging markets for Daiichi-Sankyo (Geographical diversification).
Entry into non-proprietary drugs for Daiichi-Sankyo (Product Extension). To develop
new drugs to fill the gaps and take advantage of Ranbaxy’s strong areas.
Realization of sustainable growth through a complementary business model. To
overcome its current challenges in cost structure and supply chain.
Acceleration of innovation drug creation by optimizing value chain efficiency.
The acquisition of Ranbaxy by Daichi represents a major entry for the Japanese firm
into the high growth business areas of generic drug. The acquisition shows that
global pharma companies are making efforts to cope up with strong generic drug
makers.
To match the competitor's strategy.
6. Nature of transaction
All cash transaction.
Specific nature of the transaction –Off Market Transaction
Acquisition funded through debt and existing cash reserves.
The deal was financed through a mix of bank debt facilities
and existing cash resources of Daiichi Sankyo.
Daiichi-Sankyo has taken short and long term loans of USD 2.6
billion which is almost 50% of the total funding requirement
of the deal.
7. Involved Parties
Daiichi-Sankyo
• Nomura Securities Co., Ltd., the Japan headquartered
investment bank, acted as the exclusive financial
advisor
• Jones Day as the legal advisor outside India
• P&A Law Offices as the legal advisor in India
• Mehta Partners LLC as the strategic business advisor
and
• Ernst & Young as the accounting and tax advisor
8. Contd…
Ranbaxy Co Ltd
• Religare Capital Markets Limited, a wholly owned
subsidiary of Religare Enterprises Limited, is the
exclusive financial advisor to Ranbaxy and the Singh
family.
• Vaish Associates are the legal advisors to Ranbaxy
and the Singh family
9. Synergies
Considering that Ranbaxy is a generics company and Daiichi Sankyo an
innovator company, both the businesses complement each other with
negligible overlap.(Daiichi will support Ranbaxy's R&D efforts and contract
research business)
Ranbaxy provides a low cost manufacturing set-up to Daiichi Sankyo.
Ranbaxy geographically diversified presence across the globe will enable it
to provide a wider reach to Daiichi Sankyo' product portfolio, including
India.
Ranbaxy has a small presence in the Japanese market where the generics
market holds good opportunities.
Ranbaxy incurred lower interest costs, as it became debt-free company.
10. Contd….
The deal strengthened the financials of Ranbaxy (making it debt free and
cash rich) and help it grow aggressively -organic.
Ranbaxy bypassed a lot of European and U.S. companies that were finding it
difficult to enter the Japanese market, where safety and testing
requirements are a lot higher.
This deal made the amalgamated company to be the 15th largest pharma
company in the world.
The below equation solves for the minimum required synergy:
Pre – Merger Value of both the firms + Synergy
= Post – Merger Stock Price
Post – Merger Number of shares
11. The Deal
Daiichi-Sankyo acquired 34.8% stake in Ranbaxy on 11th June,
2008
It made an open offer to the Ranbaxy shareholders for
another 20%
Picked up another 9.12% through preferential allotment
It was an all cash transaction.
Size of the deal: US$ 4.9 Billion
As per the deal, total value of Ranbaxy was US $ 8.5 Billion.
13. Anticipated Benefits Of the Acquisition
Daiichi-Sankyo
• Strengthen the position of the company.
• Acquisition will provide low cost manufacturing.
• Market access to over 60 countries .
Ranbaxy Co Ltd
• Company will become one of the top 5 in generic business.
• Access to Daiichi’s advanced R & D facilities.
• Access to Japanese drug market
• Infusion of an additional $ 1 billion into the company.
• Surplus cash of Rs.3,000 crores flows in.
• The market capitalization goes to $8billion & the net worth goes up.
14. Market Reaction To The Acquisition
Announcement-2008
Share price of Ranbaxy rose from 3.86% to Rs 526.40 on June 9th
Daiichi Sankyo agreed to pay as much as $4.6 billion for a 50.1%
stake in Ranbaxy
The stock ended almost flat at Rs 560.80 on June 11th .
June 13- it spiked to Rs 660 and settled at 567.75 points, up a
mere 0.15%.
17. How did Daiichi-Sankyo
acquire Ranbaxy?
Acquisition
Nature of Transaction
Consideration
(in Crores)
Open Market Share Purchase 7458
Share Purchases from founding family 10169
Share Purchases by issue of new Share 3742
Direct acquisition related expenditures 131
TOTAL 21500
Rs 21,500 Crores (USD 4.9 Billion)
18. Valuation of Ranbaxy
Value
Assets and Liabilities attributed
(Rs Crores)
Book value of assets and liabilities (Cash, Inventory
3470
etc.)
Inventories (Increase in inventories to fair value) 88
Tangible assets (Land) 440
Intangible assets (Leasehold land) 260
Intangible assets (Increase in current products,
1805
etc. to fair value)
In-process R&D expenses 304
Deferred tax liability -881
Minority Interests -1981
Goodwill 17995 USD 4.01 Billion
Total consideration 21500 USD 4.9 Billion
19. Interpretation Of Shares Held
Pre & Post Acquisition
SHARES HELD BY PRE % POST % CHANGE %
SINGH 34.82 - (100)
SINGH’S FAMILY 19 - (100)
DAIICHI SANKYO - 63.92 63.92
MUTUAL FUND 5.56 2.58 (53.59)
BANKS 1.71 0.32 (58.47)
INSURANCE COMPANY 14.39 9.19 (36.13)
F.I.I 12.42 4.41 (64.49)
GENERAL PUBLIC 12.1 19.53 61.40
20. Reasons for higher valuation
The deal values Ranbaxy at $8.42 billion -
• An enterprise value to sales (EV/sales) of 3.5x the estimated
earnings for 2008.
• An EV/EBITDA of 23x the forward earnings for the current year.
It was a very attractive multiple.
Daiichi Sankyo paid about 4.7x Ranbaxy’s sales for the acquisition, as
against2.7x paid by Mylan for Merck KGaA’s generic unit at a price of for
$7.6 billion in 2007.
The high valuation was due to Ranbaxy’s strong infrastructure, presence
across geographies, a robust product pipeline, including upsides from the
settlements.
24. Impact Analysis of the deal on
Daiichi’s Figures
The EPS showed a double fold increase without much of increase in
gross profit which indicated that the reserves & surplus should have
been made available accordingly.
The balance sheet of Daiichi Sankyo indicated that the current
liabilities had increased to 161% when compared to current assets
which had decreased by (15.43%).
COGS significantly decreased in the year 2008 due to the increase in
Purchase of Investments owing to the acquisition.
25. Where did Daiichi fail: Due
Diligence
Daiichi Sankyo though learnt about the US FDA Invocation
ignored it expecting it to get resolved.
Lack of proper due diligence. Daiichi, in its eagerness to tap the
expertise of a generic drug maker, took the risk of buying
Ranbaxy for top dollar.
Three weeks after the deal, Daiichi reported currency-exchange
losses of nine billion rupees in 2008 owing to the Goodwill
evaluation at the time of acquisition.
26. The Final Verdict
• Verdict: Failure
This is a classic example of an acquirer paying top price without
looking too closely at the quality of the goods.
“ Daiichi continues to pay for the huge risk it took in the deal”
• Stock market verdict
Ranbaxy shares have staged a huge rally since hitting a low of 133
rupees in March 2009, trading at 465 rupees on March 14, 2011.
27. Acquisition Analysis
View of Daiichi on the FDA issue
It termed the event as a “risk call” and decided to tackle it when presented
with the problem rather than spend time evaluating the risk.
Daiichi’s lack of understanding of generic business in the valuation paid for
acquiring Ranbaxy.
Inadequate due diligence done considering the size, scale and scope of the
deal.
Should have estimated the full extent of the legal risk arising out of the US
FDA letters,
In May 2009, Daiichi-Sankyo announced a one-time write-down of $3.45 billion of
Goodwill.
Daiichi worried about the financial losses and the FDA restrictions.
28. Regulatory/ Forex/ Legal Issues
Involved
Approval of Foreign Investment Promotion Board
(“FIPB”)
Approval under Press Note No. 1 (2005) from SEBI
Daiichi was already holding equity stake in Uni-Sankyo
Limited, a company engaged in ‘same’ business as
Ranbaxy, prior approval of FIPB was obtained.
Approval of Cabinet Committee on Economic Affairs
(“CCEA” )
Final clearance was received from CCEA by Daiichi in the
month of October, 2008.
29. Taxation Issues Involved
• Slump in the financial markets - the prices of
Ranbaxy dropped to around Rs.265 (approx).
• Promoters sought SEBI approval to waive the +1%
ceiling for this block deal.
• Huge difference between the deal price and the
existing market price - permission was not granted by
SEBI
• Off market deal was executed after paying the capital
gains tax.
30. Corporate Law Issues Involved
• Nomination of Independent Director as per the
Agreement, post completion
• The board of directors of Ranbaxy would consist of 10
directors, in a combination of
– 4 independent and non-independent directors will be
nominated by the Promoters
– 6 independent and non-independent directors will be
nominated by Daiichi.
31. Major M&As in the Global Pharma industry
Company Target company $ billion
Pfizer Wyeth 68
Merck Schering Plough 41
Bayer Schering 19.7
Schering Plough Organon 14.5
Takeda Nycomed 13.6
Sankyo Daiichi 7.7
32. Drivers of M&A In The Global Pharma
Industry
Lack of research and development (R&D) productivity
Expiring patents.
Participating in generics to maintain market share
High profile product recalls
Expansion into emerging markets
Revitalizing growth in mature markets
Leveraging operations to achieve greater economies of scale
33. India - Advantages
Leveraging India’s low cost advantage by shifting manufacturing base to
India
Indian companies have superior biotech and drug synthesis skills, high
quality and vertically integrated manufacturing assets, differentiated
business models
Acquired companies serve as an effective front end for Indian companies in
developed markets.
Price controls have been relaxed and there have been significant changes in
the medicinal requirements of the Indians
Manufacturing base in India is strong enough to support international
pharmaceutical companies from performance perspective
35. Global Scenario Of M&A Deals
For large firms, mergers are a response to expected excess capacity that is
triggered by patent expirations and gaps in the pipeline of follow-on
products, which depresses expected future earnings growth.
Mergers are in fact often rationalized as offering an opportunity to reduce
overhead and other costs, implying expectations of economies of scale.
For small firms mergers appear to be primarily an exit strategy for firms that
are in financial trouble